Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
Home
  • Home

Refine search

Refine search

Access:
Content type:
Publication date:
Apply
Subject: Show more
Journals Show more
Publishers: Show more
Societies Show more
Series: Show more
Collections: Show more

Actions for selected content:

Select all | Deselect all
  • View selected items
  • Export citations
  • Download PDF (zip)
  • Send to Kindle
  • Send to Dropbox
  • Send to Google Drive

Save Search

You can save your searches here and later view and run them again in "My saved searches".

Please provide a title, maximum of 40 characters.
Cancel
×

108 results

Page 1 of 6

  • P03-36 - A new Neurocognitive Scale for Schizophrenia Which Could be Used in Daily Practice
  • F. Bretel, G. Opolczynski, C. Cognard, C. Soyer, G. Birien, V. Bourgeois, N. Franck, S. Haouzir, O. Guillin
  • Journal: European Psychiatry / Volume 25 / Issue S1 / 2010
  • Published online by Cambridge University Press: 17 April 2020, p. 1
    • Article
    • Access
    • PDF
    • Export citation
  • View abstract
    Background

    Neurocognition is impaired in patients with schizophrenia, and almost all patients demonstrate some measure of decline from their expected level. Neurocognitive impairment is a core feature of schizophrenia and is the single strongest correlate of real-world functioning. To date, several instruments can measure neurocognition, but none of them could be used in daily clinical practice because of their long duration of assessment or the high level of training needed to use them. The aim of the present study was to create a scale that measures different neurocognitive domains usually impaired in schizophrenia (attention, work memory, verbal memory and executive functions).

    Method and results

    40 patients with schizophrenia according to DSM-IV-TR criteria have been included in the study and 100% of the patients have been able to complete the scale, that was generally well accepted. Neurocognition was also evaluated in some of the patients with the WAIS-III to compare the scores with our new and not validated scale. Psychiatrists, neuropsychologists and ergotherapists administered the scale. Inter-ratter reliability was evaluated. The time to complete the scale was not more than 10 minutes. Results are under analysis and will be presented during the meeting.

    Conclusion

    Measuring neurocognition in daily practice is crucial to better evaluate the effect on neurocognition of pharmacological and none pharmacological cares in schizophrenia.

  • Analysis of the seasonal variation of schizophrenic births using a Kolmogorov-Smirnov type statistic
  • H Verdoux, N Takei, R Cassou de Saint-Mathurin, M Bourgeois
  • Journal: European Psychiatry / Volume 12 / Issue 3 / 1997
  • Published online by Cambridge University Press: 16 April 2020, pp. 111-116
  • View abstract

    Previous studies have shown that schizophrenic patients are more likely to be born in winter or early spring months than the general population. Data on 4,207 patients with a hospital diagnosis of schizophrenia were obtained from a mailed survey to public departments of adult psychiatry in metropolitan France. For each year from 1900 to 1965, the expected monthly number of schizophrenic births was calculated and any seasonal variation of live births in the general population was taken into account. Cumulative distributions of the observed and expected number of schizophrenic births were compared using a Kolmogorov-Smirnov type statistic. The seasonal distribution of schizophrenic births was significantly different from that of the general population (P < 0.01). An excess of schizophrenic births was found in the first half of the year, with a peak in April (+ 13%).

The Epilepsy Prescriber's Guide to Antiepileptic Drugs
  • The Epilepsy Prescriber's Guide to Antiepileptic Drugs
  • 2nd edition
  • Philip N. Patsalos
  • Edited by Blaise F. D. Bourgeois
  • Published online: 05 June 2014
  • Print publication: 21 November 2013
  • View description
    This practical and concise book is an essential reference guide for use by all clinicians and allied health professionals that treat or care for patients with epilepsy. In full color throughout, this volume presents the antiepileptic drugs (AEDs), 34 in total, in alphabetical order and for each AED the information is divided into eight colored sections: general therapeutics, pharmacokinetics, interaction profile, adverse effects, dosing and use, special populations, overview, and suggested reading. This second edition has been extensively revised and updated. Specific additions include: inclusion of the new drugs perampanel and retigabine (also called ezogabine)updated pharmacokinetic interactionssuggested pediatric dosing schedules for several drugsdiscussion about bone health, and vitamin D monitoring and supplementationinformation on teratogenicity in the sections on pregnancy. This handy pocket book will be an excellent companion for all clinicians that treat patients with epilepsy.

Page 1 of 6